Mirae Asset Capital Life Science
Overview
Mirae Asset Capital Life Science is a venture capital firm that invests in private biotechnology companies from seed to series C with a primary focus on therapeutics, diagnostics, and AI/ML tools for drug discovery.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Dren Bio | Oct 2026 | Early Funding | Co-investor |
| Precede Biosciences | Jan 2026 | Series B | Co-investor |
| Attovia Therapeutics | Apr 2025 | Series C | Co-investor |
| Accent Therapeutics | Jan 2024 | Series C | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Mirae Asset Capital Life Science based?
Mirae Asset Capital Life Science is headquartered in Boston, Massachusetts, United States.
When was Mirae Asset Capital Life Science founded?
Mirae Asset Capital Life Science was founded in 2023.
How many portfolio companies does Mirae Asset Capital Life Science have?
Mirae Asset Capital Life Science has 4 portfolio companies in Caplight's dataset.
What are some companies in Mirae Asset Capital Life Science's portfolio?
Recent investments visible on Caplight include Dren Bio, Precede Biosciences, Attovia Therapeutics, Accent Therapeutics.
What was Mirae Asset Capital Life Science's most recent investment?
Mirae Asset Capital Life Science's most recent investment on Caplight was in Dren Bio in 2026.
What sectors does Mirae Asset Capital Life Science focus on?
Mirae Asset Capital Life Science focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Mirae Asset Capital Life Science focus on?
Mirae Asset Capital Life Science typically invests at the Mid stage.
What is Mirae Asset Capital Life Science's AUM?
Mirae Asset Capital Life Science's assets under management are estimated between $50.0M and $50.0M.